Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Alpha Cognition Inc
C.ACOG
Alternate Symbol(s):
ACOG
Healthcare
Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062...
is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (CSE:ACOG)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
(521)
•••
TrevorAbes
X
Post by
TrevorAbes
on Jul 30, 2024 8:04am
FDA approves Alpha Cognition's Zunveyl to treat Alzheimer's
Growth runway activated: https://stockhouse.com/news/the-market-online-news/2024/07/29/fda-approves-alpha-cognition-s-zunveyl-to-treat-alzheimer-s-disease
(94)
•••
G1945V
X
Post by
G1945V
on Jul 29, 2024 11:09am
(FDA) has granted approval for ZUNVEYL® AKA, ALPHA-1062,
https://www.businesswire.com/news/home/20240729327804/en/ G1945V
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(8)
•••
TheMedia
X
Post by
TheMedia
on Mar 29, 2024 2:53pm
Ouch!
Not sure what this poor company paid the duds @ Equity Guru to pump the stock the results from the Equity Guru will be ZERO! Stop paying Chris Parry to do nothing.
(59)
•••
Nibinator
X
Post by
Nibinator
on Dec 09, 2023 7:30am
I see goooold here
OPEN I.P.O.
(59)
•••
Nibinator
X
Post by
Nibinator
on Dec 08, 2023 1:38pm
That i.p.o. oh hoho
Still open
(59)
•••
Nibinator
X
Post by
Nibinator
on Dec 08, 2023 10:04am
They should be on nasdaq
Boom
(94)
•••
G1945V
X
Post by
G1945V
on Aug 14, 2023 5:13pm
Business Wire:
Alpha Cognition Receives Notice of Allowance for U.S. Patent Application covering use of ALPHA-1062 for Mild to Moderate Alzheimer's Disease G1945V
(0)
•••
StreamlineCap
X
Post by
StreamlineCap
on Jul 22, 2023 1:08am
Up 64% this month...
Is there any news with the NDA being filed? Stock is trading like the company is breathing new life.
(94)
•••
G1945V
X
Post by
G1945V
on Sep 02, 2022 12:37pm
Zacks Small-Cap Research
September 2, 2022 John D. Vandermosten, CFA https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_09022022_ACOGF_Vandermosten.pdfZacks G1945V
(144)
•••
culturedpiggy01
X
Post by
culturedpiggy01
on Apr 22, 2022 5:49pm
$ACOG.v announces new CFO and additions to the board
$ACOG.v recently announced the appointment of Don Kalkofen as Chief Financial Officer (CFO) and Michael McFadden, $ACOG ‘s CEO, to the board of directors https://ca.finance.yahoo.com/news/alpha
...more
(21)
•••
StockHawk1
X
Post by
StockHawk1
on Apr 20, 2022 5:26pm
$ACOG gets positive preclinical results for ALPHA-0602 drug
For those interested in the biopharma space, Alpha Cognition Inc. ($ACOG.v $ACOGF) is a company working on creating medication to help those with neurodegenerative disorders. It recently announced
...more
(273)
•••
partystocker
X
Comment by
partystocker
on Apr 19, 2022 12:42pm
RE:$ACOG appoints new CFO
Some solid gains on the chart for $ACOG.v the past few days. Shares are up a solid 13% and holding!
(43)
•••
Stockydoc
X
Post by
Stockydoc
on Apr 18, 2022 4:29pm
$ACOG appoints new CFO
Last week, $ACOG announced they have appointed Don Kalkofen as CFO. Mr. Kalkofen has plenty of experience in the biotechnology industry and has been successful in the past serving as CFO of
...more
(273)
•••
partystocker
X
Post by
partystocker
on Apr 17, 2022 1:30pm
$ACOG.v Updates
As Alpha Cognition (TSXV: ACOG) enters its next phase of growth, the company has appointed Don Kalkofen as CFO. Don has considerable experience in corporate finance, as well as a strong track record
...more
(268)
•••
stockpatrol
X
Post by
stockpatrol
on Apr 13, 2022 6:27pm
You can check out $ACOG.v $ACOGF ’s pre-clinical data from A
You can check out $ACOG.v $ACOGF ’s pre-clinical data from ALPHA-1062 here https://twitter.com/alpha_cognition/status/1514292342857121796 The data is promising, FDA
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments